[Comment] Neoadjuvant therapy in melanoma: the next step?

Active drugs for the treatment of advanced melanoma are now available, including combinations of BRAF plus MEK inhibitors for BRAF-mutant melanoma and immune-checkpoint blockers for all melanomas regardless of BRAF status, especially regimens based on PD-1.1 What works in the advanced setting is also effective in the adjuvant setting, especially the combination of dabrafenib and trametinib in patients with stage III BRAF-mutant melanoma2 and nivolumab for all melanoma types in patients with stage IIIB or IIIC –IV disease.

Source: The Lancet Oncology - January 17, 2018 Category: Cancer & Oncology Authors: Paolo A Ascierto, Alexander M M Eggermont Tags: Comment Source Type: research